These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
154 related articles for article (PubMed ID: 27809878)
1. Synuclein-γ (SNCG) expression in ovarian cancer is associated with high-risk clinicopathologic disease. Strohl A; Mori K; Akers S; Bshara W; Buttin B; Frederick PJ; Helenowski IB; Morrison CD; Odunsi K; Schink JC; Scholtens DM; Wei JJ; Kim JJ J Ovarian Res; 2016 Nov; 9(1):75. PubMed ID: 27809878 [TBL] [Abstract][Full Text] [Related]
2. Synuclein-γ in uterine serous carcinoma impacts survival: An NRG Oncology/Gynecologic Oncology Group study. Winder AD; Maniar KP; Wei JJ; Liu D; Scholtens DM; Lurain JR; Schink JC; Buttin BM; Filiaci VL; Lankes HA; Ramirez NC; Park K; Singh M; Lieberman RW; Mannel RS; Powell MA; Backes FJ; Mathews CA; Pearl ML; Secord AA; Peace DJ; Mutch DG; Creasman WT; Kim JJ Cancer; 2017 Apr; 123(7):1144-1155. PubMed ID: 27926776 [TBL] [Abstract][Full Text] [Related]
3. Neuronal protein synuclein gamma predicts poor clinical outcome in breast cancer. Guo J; Shou C; Meng L; Jiang B; Dong B; Yao L; Xie Y; Zhang J; Chen Y; Budman DR; Shi YE Int J Cancer; 2007 Sep; 121(6):1296-305. PubMed ID: 17534899 [TBL] [Abstract][Full Text] [Related]
4. The role of CpG islands hypomethylation and abnormal expression of neuronal protein synuclein-gamma (SNCG) in ovarian cancer. Czekierdowski A; Czekierdowska S; Wielgos M; Smolen A; Kaminski P; Kotarski J Neuro Endocrinol Lett; 2006 Jun; 27(3):381-6. PubMed ID: 16816827 [TBL] [Abstract][Full Text] [Related]
5. Expression of neuronal protein synuclein gamma gene as a novel marker for breast cancer prognosis. Wu K; Quan Z; Weng Z; Li F; Zhang Y; Yao X; Chen Y; Budman D; Goldberg ID; Shi YE Breast Cancer Res Treat; 2007 Mar; 101(3):259-67. PubMed ID: 16821081 [TBL] [Abstract][Full Text] [Related]
6. Overexpression of synuclein-γ predicts lack of benefit from radiotherapy for breast cancer patients. Min L; Zhang C; Ma R; Li X; Yuan H; Li Y; Chen R; Liu C; Guo J; Qu L; Shou C BMC Cancer; 2016 Sep; 16(1):717. PubMed ID: 27595752 [TBL] [Abstract][Full Text] [Related]
7. Ascites regression following neoadjuvant chemotherapy in prediction of treatment outcome among stage IIIc to IV high-grade serous ovarian cancer. Xu X; Deng F; Lv M; Ren B; Guo W; Chen X J Ovarian Res; 2016 Dec; 9(1):85. PubMed ID: 27912779 [TBL] [Abstract][Full Text] [Related]
8. Identification of γ-synuclein as a stage-specific marker in bladder cancer by immunohistochemistry. Zhao J; Xing N Med Sci Monit; 2014 Dec; 20():2550-5. PubMed ID: 25479371 [TBL] [Abstract][Full Text] [Related]
9. Predictive and prognostic values of BubR1 and synuclein-gamma expression in breast cancer. Cirak Y; Furuncuoglu Y; Yapicier O; Alici S; Argon A Int J Clin Exp Pathol; 2015; 8(5):5345-53. PubMed ID: 26191236 [TBL] [Abstract][Full Text] [Related]
10. Survival impact of surgical cytoreduction in stage IV epithelial ovarian cancer. Bristow RE; Montz FJ; Lagasse LD; Leuchter RS; Karlan BY Gynecol Oncol; 1999 Mar; 72(3):278-87. PubMed ID: 10053096 [TBL] [Abstract][Full Text] [Related]
11. [SNCG expression and clinical significance in colorectal cancer liver metastasis]. Guo CG; Sun LC; Liu Q; Xie YB; Wang X Zhonghua Wei Chang Wai Ke Za Zhi; 2012 Jun; 15(6):625-8. PubMed ID: 22736138 [TBL] [Abstract][Full Text] [Related]
12. Expression of γ-Synuclein in Bladder Carcinoma: A Possible Marker for Prognosis. Chen Z; Ji Z; Wang Q; Shi B; Shou C; Liu C; Fan H; Li H; Davidson KT; Wakefield MR; Ball TW; Fang Y Anticancer Res; 2016 Mar; 36(3):951-6. PubMed ID: 26976983 [TBL] [Abstract][Full Text] [Related]
13. Expression of synuclein gamma indicates poor prognosis of triple-negative breast cancer. Wu K; Huang S; Zhu M; Lu Y; Chen J; Wang Y; Lin Q; Shen W; Zhang S; Zhu J; Shi YE; Weng Z Med Oncol; 2013; 30(3):612. PubMed ID: 23696021 [TBL] [Abstract][Full Text] [Related]
14. Association of Somatic Mutations of ADAMTS Genes With Chemotherapy Sensitivity and Survival in High-Grade Serous Ovarian Carcinoma. Liu Y; Yasukawa M; Chen K; Hu L; Broaddus RR; Ding L; Mardis ER; Spellman P; Levine DA; Mills GB; Shmulevich I; Sood AK; Zhang W JAMA Oncol; 2015 Jul; 1(4):486-94. PubMed ID: 26181259 [TBL] [Abstract][Full Text] [Related]
15. Combined phenotype of 4 markers improves prognostic value of patients with colon cancer. Liu C; Qu L; Dong B; Xing X; Ren T; Zeng Y; Jiang B; Meng L; Wu J; Shou C Am J Med Sci; 2012 Apr; 343(4):295-302. PubMed ID: 22261620 [TBL] [Abstract][Full Text] [Related]
16. Synuclein gamma predicts poor clinical outcome in colon cancer with normal levels of carcinoembryonic antigen. Liu C; Dong B; Lu A; Qu L; Xing X; Meng L; Wu J; Eric Shi Y; Shou C BMC Cancer; 2010 Jul; 10():359. PubMed ID: 20604972 [TBL] [Abstract][Full Text] [Related]
17. Impact of complete cytoreduction leaving no gross residual disease associated with radical cytoreductive surgical procedures on survival in advanced ovarian cancer. Chang SJ; Bristow RE; Ryu HS Ann Surg Oncol; 2012 Dec; 19(13):4059-67. PubMed ID: 22766983 [TBL] [Abstract][Full Text] [Related]
18. Abnormal activation of the synuclein-gamma gene in hepatocellular carcinomas by epigenetic alteration. Zhao W; Liu H; Liu W; Wu Y; Chen W; Jiang B; Zhou Y; Xue R; Luo C; Wang L; Jiang JD; Liu J Int J Oncol; 2006 May; 28(5):1081-8. PubMed ID: 16596223 [TBL] [Abstract][Full Text] [Related]
19. High levels of pretreatment CA125 are associated to improved survival in high grade serous ovarian carcinoma. Morales-Vásquez F; Pedernera E; Reynaga-Obregón J; López-Basave HN; Gómora MJ; Carlón E; Cárdenas S; Silva-Ayala R; Almaraz M; Méndez C J Ovarian Res; 2016 Jul; 9(1):41. PubMed ID: 27388275 [TBL] [Abstract][Full Text] [Related]
20. Combined expression of metastasis related markers Naa10p, SNCG and PRL-3 and its prognostic value in breast cancer patients. Min L; Ma RL; Yuan H; Liu CY; Dong B; Zhang C; Zeng Y; Wang L; Guo JP; Qu LK; Shou CC Asian Pac J Cancer Prev; 2015; 16(7):2819-26. PubMed ID: 25854368 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]